cephalosporin c has been researched along with ceftobiprole in 196 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 85 (43.37) | 29.6817 |
| 2010's | 76 (38.78) | 24.3611 |
| 2020's | 35 (17.86) | 2.80 |
| Authors | Studies |
|---|---|
| Angehrn, P; Hebeisen, P; Heinze-Krauss, I; Hohl, P; Page, MG; Then, RL | 1 |
| Entenza, JM; Glauser, MP; Heinze-Krauss, I; Hohl, P; Moreillon, P | 1 |
| Pünter, V; von Graevenitz, A; Zbinden, R | 1 |
| Bowker, KE; Holt, HA; MacGowan, AP; Wootton, M | 1 |
| Biedenbach, DJ; Deshpande, LM; Jones, RN; Mutnick, AH | 1 |
| Deshpande, LM; Jones, RN | 1 |
| Issa, NC; Patel, R; Piper, KE; Rouse, MS; Steckelberg, JM; Wilson, WR | 1 |
| Azoulay-Dupuis, E; Bédos, JP; Mohler, J; Schleimer, M; Schmitt-Hoffmann, A; Shapiro, S | 1 |
| Mouton, JW; Nashed, N; Punt, NC; Schmitt-Hoffmann, A; Shapiro, S | 1 |
| Georgopapadakou, N | 1 |
| Brown, T; Kovács, P; Man, A; Nashed, N; Perez, A; Roos, B; Sauer, J; Schleimer, M; Schmitt-Hoffmann, A; Weidekamm, E | 1 |
| Brown, T; Man, A; Nashed, N; Nyman, L; Roos, B; Sauer, J; Schleimer, M; Schmitt-Hoffmann, A; Weidekamm, E | 1 |
| Anderegg, TR; Jones, RN; Sader, HS | 1 |
| Deshpande, L; Fritsche, TR; Jones, RN; Rhomberg, PR; Sader, HS | 1 |
| Chambers, HF | 2 |
| Appelbaum, PC; Bozdogan, B; Clark, C; Credito, K; Dewasse, B; Hoellman, DB; Kosowska, K; Lin, G; McGhee, P; Shapiro, S | 1 |
| Bento, M; Gjinovci, A; Lew, DP; Li, D; Schrenzel, J; Vaudaux, P | 1 |
| de Roux, A; Lode, H; Schmidt-Ioanas, M | 1 |
| Appelbaum, PC; Bogdanovich, T; Ednie, LM; Shapiro, S | 1 |
| Becker, K; Friedrich, AW; Peters, G; von Eiff, C | 1 |
| Appelbaum, PC | 1 |
| Livermore, DM | 1 |
| Anguita-Alonso, P; Hein, MM; Patel, R; Rouse, MS; Steckelberg, JM | 1 |
| Appelbaum, PC; Bogdanovich, T; Clark, C; Ednie, L; Lin, G; Shapiro, S; Smith, K | 1 |
| Bush, K; Davies, TA; Shang, W | 1 |
| De Mendonça, R; De Ryck, R; Denis, O; Deplano, A; Hallin, M; Nonhoff, C; Struelens, MJ; Vanhoof, R | 1 |
| Citron, DM; Fernandez, HT; Goldstein, EJ; Merriam, CV; Tyrrell, KL; Warren, YA | 1 |
| Appelbaum, PC; Pankuch, GA | 1 |
| Dalziel, C; Turner, B | 1 |
| Appelbaum, PC; Ednie, L; Shapiro, S | 1 |
| Bush, K; Heep, M; Macielag, MJ; Noel, GJ | 1 |
| Bush, K; Drusano, GL; Kahn, JB; Kimko, HC; Lodise, TP; Murthy, BP; Noel, GJ; Pypstra, R | 1 |
| Arias, CA; Murray, BE; Panesso, D; Singh, KV | 1 |
| Archer, G; Cuirolo, A; Faccone, D; Goldstein, F; Kitzis, MD; Ly, A; Morris, J; Perutka, J; Plata, K; Rosato, AE; Sournia, A | 1 |
| Andrew, T; Bush, K; Davies, TA; Kania, M; Page, MG; Shang, W | 1 |
| Goldstein, FW | 1 |
| Jones, ME | 1 |
| Noel, GJ | 1 |
| Rossolini, GM | 1 |
| Bush, K; Kania, M; Page, MG; Queenan, AM; Shang, W | 1 |
| Ellis, MW; Jorgensen, JH; Yun, HC | 1 |
| Appelbaum, PC; Lin, G | 1 |
| Loffler, CA; Macdougall, C | 1 |
| Thamlikitkul, V; Trakulsomboon, S | 1 |
| McAllister, S; McGowan, JE; Srinivasan, V; Tenover, FC | 1 |
| Aranza, MK; Pillar, CM; Sahm, DF; Shah, D | 1 |
| Widmer, AF | 1 |
| Aksoy, DY; Unal, S | 1 |
| Banerjee, R; Basuino, L; Chambers, HF; Gretes, M; Strynadka, N | 1 |
| Fritsche, TR; Gorodecky, E; Jones, RN; Lodise, TP; Patel, N; Renaud-Mutart, A | 1 |
| Deresinski, SC | 2 |
| Fritsche, TR; Jones, RN; Sader, HS | 1 |
| Decorby, M; Hoban, DJ; Karlowsky, JA; Nichol, K; Walkty, A; Zhanel, GG | 1 |
| Laohavaleeson, S; Nicolau, DP; Tessier, PR | 1 |
| Antignac, A; Chung, M; Kim, C; Tomasz, A | 1 |
| Cheung, CM; Leonard, SN; Rybak, MJ | 1 |
| Gin, AS; Hoban, DJ; Karlowsky, JA; Lam, A; Noreddin, AM; Rubinstein, E; Schweizer, F; Thomson, K; Walkty, A; Zhanel, GG | 1 |
| Amsler, KM; Bush, K; Davies, TA; Jacobs, MR; Shang, W | 1 |
| Abrahamian, FM; Deblieux, PM; Emerman, CL; Kollef, MH; Kupersmith, E; Leeper, KV; Paterson, DL; Shorr, AF | 1 |
| Chen, M; Liu, Y; Sun, H; Wang, H; Xie, X; Xu, Y | 1 |
| Andes, DR; Craig, WA | 1 |
| Bishop, A; Chan, P; Gole, D; Jimidar, IM; Kupiec, TC; Trissel, LA; Vermeersch, H | 1 |
| Decker, CF; Johnson, MD | 1 |
| French, GL | 1 |
| Kimko, H; Murthy, B; Nandy, P; Noel, GJ; Strauss, R; Xu, X | 1 |
| Micek, ST; Neuner, EA; Ritchie, DJ | 1 |
| Barbour, A; Derendorf, H; Rand, KH; Schmidt, S | 1 |
| Duval, V; Glupczynski, Y; Joris, B; Lemaire, S; Tulkens, PM; Van Bambeke, F | 1 |
| Amsler, KM; Bajaksouzian, S; Bush, K; Davies, TA; Jacobs, MR; Shang, W | 1 |
| Barbour, A; Derendorf, H; Grant, M; Murthy, B; Sabarinath, SN; Schmidt, S; Seubert, C; Skee, D | 1 |
| Espinal, P; Marti, S; Sánchez-Céspedes, J; Vila, J | 1 |
| Baum, EZ; Bush, K; Crespo-Carbone, SM; Davies, TA; Foleno, BD; He, W; Morrow, BJ; Queenan, AM | 1 |
| Drusano, GL; Gotfried, M; Kahn, JB; Khashab, M; Laohavaleeson, S; Lodise, TP; Murray, SA; Nicholson, S; Nicolau, DP; Noel, GJ; Rodvold, KA; Tessier, PR | 1 |
| Hoban, DJ; Karlowsky, JA; Nichol, K; Noreddin, AM; Voth, D; Zhanel, GG | 1 |
| Ganea, GM; Goetz, RM; Stein, RA | 1 |
| El Solh, A | 1 |
| Bagchi, P; Kimko, H; Nandy, P; Noel, GJ; Samtani, MN; Strauss, RS; Xu, X | 1 |
| Corvec, S; Cremet, L; Drugeon, H; Lepelletier, D; Reynaud, A | 1 |
| Green, K; Low, DE; McGeer, A; Patel, SN; Pillai, DR; Pong-Porter, S | 1 |
| Cabeza, J; Carrasco, C; Gutierrez, J; Sorlozano, A; Villegas, E | 1 |
| Deresinski, SC; Schirmer, PL | 1 |
| Eliopoulos, GM | 1 |
| Abbanat, D; Bush, K; Fernandez, J; Flamm, RK; Hilliard, JJ; Melton, JL; Santoro, CM; Zhang, W | 1 |
| Basuino, L; Bauer, D; Chambers, HF; Diep, BA; Tattevin, P | 1 |
| Amoroso, A; Coyette, J; Henry, X; Joris, B | 1 |
| Bush, K; Davies, TA; Flamm, RK; Shang, W | 1 |
| Cattoir, V; Daurel, C | 1 |
| Kollef, MH | 1 |
| Bongiorno, D; Borbone, S; Campanile, F; Stefani, S | 1 |
| Araújo, C; Gonçalves, A; Igrejas, G; Poeta, P; Radhouani, H; Rodrigues, J; Silva, N | 1 |
| Appelbaum, PC; Ednie, LM; Lin, G | 1 |
| Chahine, EB | 1 |
| Dauner, DG; Nelson, RE; Taketa, DC | 1 |
| Betriu, C; Culebras, E; Gómez, M; López-Fabal, F; Picazo, JJ; Rodríguez-Avial, I | 1 |
| Elborn, JS; Parkins, MD | 1 |
| Bush, K; Flamm, RK; Queenan, AM; Shang, W | 1 |
| Bush, K; Davies, TA; Flamm, RK; He, W | 1 |
| Husain, N; Johnson, LB; Pawlak, J; Saravolatz, LD | 1 |
| Asker-Hagelberg, C; Bäckström, T; Beck, O; Nord, CE; Panagiotidis, G; Rashid, MU; Weintraub, A | 1 |
| Dryden, MS; Flamm, RK; Kozlov, RS; Läuffer, JM; Lee, E; Morrissey, I; Quintana, A; Rossolini, GM | 1 |
| Daubner, B; Pichler, WJ; Wendland, T | 1 |
| Brémont, S; Drugeon, HB; Gjoklaj, M; Kitzis, MD; Lascols, C; Leclercq, R; Legrand, P; Mérens, A; Miara, A; Moubareck, C; Muller-Serieys, C; Reverdy, ME; Roussel-Delvallez, M; Soussy, CJ | 1 |
| Donskey, CJ; Nerandzic, MM | 1 |
| Adam, HJ; Hoban, DJ; Karlowsky, JA; Laverdière, M; Walkty, A; Zhanel, GG | 1 |
| Bobba, S; Gutheil, WG; Mukherji, M; Ponnaluri, VK | 1 |
| Davies, T; Decker-Burgard, S; Körber-Irrgang, B; Kresken, M; Läuffer, J | 1 |
| Entenza, JM; Giddey, M; Majcherczyk, P; Moreillon, P; Veloso, TR; Vouillamoz, J | 1 |
| Picazo, JJ; Ríos Dueñas, E; Rodríguez-Avial, I | 1 |
| Murray, BE; Singh, KV | 1 |
| De Waele, JJ; Lipman, J; Paterson, DL; Roberts, JA; Udy, AA | 1 |
| Davies, TA; Flamm, RK; Lynch, AS | 1 |
| Danel, F; de Castro, L; Gretes, MC; Lovering, AL; Page, MG; Safadi, SS; Strynadka, NC | 1 |
| Boutrad, Y; Crémieux, AC; Dinh, A; Dumitrescu, O; Etienne, J; Lina, G; Martin, E; Massias, L; Saleh-Mghir, A; Vandenesch, F | 1 |
| Andes, DR; Craig, WA; Lee, DG; Murakami, Y | 1 |
| Mouton, JW; Muller, AE; Punt, N; Schmitt-Hoffmann, AH | 1 |
| Beaume, M; Francois, P; Harrison, PF; Hernandez, D; Howden, BP; Schrenzel, J; Seemann, T; Stinear, TP | 1 |
| Chen, CM; Chen, WY; Chen, YH; Chen, YS; Cheng, YJ; Chiang, PC; Chuang, YC; Hsu, GJ; Hsueh, PR; Huang, CH; Jang, TN; Ko, WC; Kung, HC; Lee, CM; Lee, MH; Liao, CH; Lin, HC; Liu, CE; Liu, CY; Liu, JW; Liu, YC; Lu, CT; Lu, PL; Pan, SC; Shi, ZY; Sun, W; Tsao, SM; Wang, LS; Yang, JL; Yu, KW | 1 |
| Barbour, AM; Derendorf, H; Rand, K; Schmidt, S; Zhuang, L | 1 |
| Abbanat, D; Amsler, K; Baum, E; Crespo-Carbone, S; Lynch, AS; Santoro, C; Shang, W | 1 |
| Anbarasu, A; Kumar, KM; Lavanya, P; Ramaiah, S | 1 |
| Ibrahim, SA; Noreddin, AM; Salem, AH; Zhanel, GG | 1 |
| Farrell, DJ; Flamm, RK; Jones, RN; Sader, HS | 2 |
| Anbarasu, A; Kumar, KM; Ramaiah, S | 1 |
| Mouton, JW; Muller, AE; Punt, N | 1 |
| Barber, KE; Ireland, CE; Nonejuie, P; Pogliano, J; Rybak, MJ; Sakoulas, G; Stone, NE; Werth, BJ | 1 |
| Holmes, NE; Howden, BP | 1 |
| Arunachalam, A; Rani, N; Thanga Velan, LP; Vijayakumar, S | 1 |
| Barber, KE; Nonejuie, P; Pogliano, J; Rybak, MJ; Sakoulas, G; Tran, KN; Werth, BJ | 1 |
| Chang, FY; Chen, RJ; Chen, YH; Chen, YS; Hsu, CW; Hsueh, PR; Jean, SS; Ko, WC; Lam, C; Lee, WS; Liao, CH; Liu, CY; Liu, JW; Lu, MC; Wu, JJ; Yu, KW | 1 |
| Basuino, L; Chambers, HF; Chan, LC; Chatterjee, SS; Diep, B; Hamilton, S | 1 |
| Costello, AJ; Deshpande, LM; Farrell, DJ; Flamm, RK; Jones, RN; Mendes, RE | 1 |
| Cillóniz, C; Liapikou, A; Torres, A | 1 |
| Alabi, A; Becker, K; Idelevich, EA; Peters, G; Schaumburg, F | 1 |
| Becker, K; Idelevich, EA; Knaack, D; Mutter, W; Peschel, A; Peters, G; Schaumburg, F; Scherzinger, AS | 1 |
| Castiglioni, A; Castiglioni, B; La Canna, G; Oltolini, C; Ossi, C; Pajoro, U; Scarpellini, P; Tassan Din, C | 1 |
| Danziger, LH; Glowacki, RC; Horn, KS; Rodvold, KA | 1 |
| Rademacher, J; Welte, T | 1 |
| Aedo, S; Alexander, JAN; Basuino, L; Chambers, HF; Chatterjee, SS; Choo, EJ; Chung, M; da Costa, TM; Hamilton, SM; Severin, A; Strynadka, NCJ; Tomasz, A | 1 |
| Gravius, S; Hilgers, C; Hischebeth, GTR; Hoerauf, A; Kohlhof, H; Molitor, E; Randau, TM | 1 |
| Engelhardt, M; Mouton, JW; Muller, AE; Punt, N; Schmitt-Hoffmann, AH | 1 |
| Hamed, K; Henriksen, AS; Smart, J | 1 |
| Bassetti, M; Cojutti, PG; De Stefanis, P; Fregonese, C; Lucchese, F; Merelli, M; Pea, F | 1 |
| Bongiorno, D; Campanile, F; Mongelli, G; Stefani, S; Zanghì, G | 1 |
| Engelhardt, M; Hamed, K; Santerre-Henriksen, A; Saulay, M; Scheeren, TWL; Welte, T | 1 |
| Duncan, LR; Flamm, RK; Hamed, KA; Mendes, RE; Pfaller, MA; Sader, HS; Shortridge, D; Smart, JI | 1 |
| Bennis, Y; Bodeau, S; Lemaire-Hurtel, AS; Leven, C; Lima, B; Quinton, MC | 1 |
| Fili, SM; Maghsudi, M; Shahabadi, N | 1 |
| Alharbi, A; Asfour, HZ; Basilim, A; Eljaaly, K; Wali, H | 1 |
| Bongiorno, D; Campanile, F; Mongelli, G; Stefani, S | 1 |
| Attanasio, V; Bernardo, M; Carozza, A; Francisci, D; Oltolini, C; Pallotto, C; Palmiero, G; Ripa, M; Scarpellini, P; Tascini, C | 1 |
| Barberán, J; Llinares, P; Mensa, J | 1 |
| Cantón, R; Díez-Aguilar, M; Morosini, MI | 1 |
| Azanza Perea, JR; Sádaba Díaz de Rada, B | 1 |
| Cillóniz, C; Dominedò, C; Garcia-Vidal, C; Torres, A | 1 |
| Morata, L; Soriano, A | 1 |
| Barberán, J | 1 |
| Grau, S | 1 |
| Aprile, A; Caio, C; Gona, F; Mezzatesta, ML; Stefani, S | 1 |
| Antonelli, A; Arena, F; Colavecchio, OL; Conte, V; Coppi, M; Di Pilato, V; Giani, T; Rossolini, GM; Santerre Henriksen, A | 1 |
| Engelhardt, M; Fowler, VG; Hamed, K; Holland, TL; Jones, ME; Saulay, M; Seifert, H | 1 |
| Hamed, K; Hawser, S; Karlowsky, JA; Kothari, N; Wiktorowicz, T | 1 |
| Millar, BC; Moore, JE; Moore, RE | 1 |
| Bethel, CR; Bonomo, RA; Desarbre, E; Kumar, V; Papp-Wallace, KM; Tang, C; van den Akker, F; Wyatt, J | 1 |
| Duployez, C; Loiez, C; Migaud, H; Senneville, E; Wallet, F | 1 |
| Andini, R; Bertolino, L; Corcione, A; Durante-Mangoni, E; Esposito, C; Karruli, A; Mazza, MC; Murino, P; Paradiso, L; Sangiovanni, F; Ursi, MP; Zampino, R | 1 |
| Horner, C; Livermore, DM; Mushtaq, S | 1 |
| Fernández, J; García-Carús, E; Rodríguez-Esteban, MÁ; Rodríguez-García, R; Telenti, M | 1 |
| Engelhardt, M; Gonzalez-Rojas, Y; Gumenchuk, I; Hamed, KA; Ionescu, D; Jones, ME; Keech, R; Kim, C; Ninov, B; Overcash, JS; Saulay, M; Simeonov, S; Smart, JI; Waters, M | 1 |
| Basso, B; Crapis, M; Della Siega, P; Garlatti, E; Pontoni, E; Rosa, R; Tonizzo, M; Venturini, S | 1 |
| Bosheva, M; Gujabidze, R; Hamed, KA; Károly, É; Nemeth, A; Saulay, M; Smart, JI | 1 |
| Baxter, M; Bergevin, M; Borgia, S; Dhami, R; Dow, G; Dube, M; Irfan, N; Karlowsky, J; Keynan, Y; Kosar, J; Lagacé-Wiens, P; MacDonald, KS; Tascini, C; Walkty, A; Zhanel, GG | 1 |
| Chao, CM; Lai, CC; Lee, GM | 1 |
| Engelhardt, M; Hamed, K; Overcash, JS; Saulay, M; Scheeren, TW; Welte, T | 1 |
| Chang, SP; Hung, SH; Lai, CC; Lan, SH; Lee, HZ; Lin, WT; Lu, LC | 1 |
| Aronica, R; Cancelli, F; Mastroianni, CM; Mauro, V; Oliva, A; Romani, F; Savellon, G; Valeri, S | 1 |
| Engelhardt, M; Gao, L; Hamed, K; Huang, H; Saulay, M | 1 |
| Bleibtreu, A; Funck-Brentano, C; Junot, H; Llopis, B; Luyt, CÉ; Noé, G; Paccoud, O; Robidou, P; Schlemmer, D; Tissot, N; Zahr, N | 1 |
| Hawser, S; Jemmely, N; Kothari, N; Redder, N | 2 |
| Cammarata, AP; Hamed, K; Litherland, K; Polak, M; Rubino, CM; Schröpf, S; Smits, A | 1 |
| Bosheva, M; Cossey, V; Gardovska, D; Hamed, K; Hornik, CD; Kwinta, P; Litherland, K; Liubsys, A; Münch, HG; Polak, M; Rubino, CM; Ruehle, C; Schröpf, S; Smits, A; Snariene, R; Tomasik, T | 1 |
| López Cortés, LE; Martínez Pérez-Crespo, PM | 1 |
| Altamimi, LA; Somily, AM | 1 |
| Antonucci, M; Artioli, S; Boni, S; D'Avolio, A; Di Perri, G; Manca, A; Martinelli, L; Nicolò, A; Pacini, G | 1 |
| Duncan, LR; Flamm, RK; Hamed, KA; Mendes, RE; Pfaller, MA; Smart, JI | 1 |
| Aubry, A; Bémer, P; Boutoille, D; Corvec, S; Deschanvres, C; Guillouzouic, A; Lakhal, K; Lecomte, R; Lepoivre, T; Navas, D; Ruffier d'Epenoux, L; Tessier, E | 1 |
| Boczar, D; Bus, K; Michalska, K | 1 |
| Bleibtreu, A; Chommeloux, J; Combes, A; Coppens, A; Hekimian, G; Junot, H; LeFevre, L; Luyt, CE; Pineton de Chambrun, M; Robert, J; Schmidt, M; Zahr, N | 1 |
| Giamarellos-Bourboulis, EJ; Leventogiannis, K; Mouktaroudi, M | 1 |
| Hsu, CK; Hsu, WH; Lai, CC | 1 |
| Bartoletti, M; Bassetti, M; Bavaro, DF; Bono, VD; Buonomo, AR; Canta, F; Carbonara, S; Congera, P; Corcione, S; De Rosa, FG; Durante-Mangoni, E; Falcone, M; Gentile, I; Giacobbe, DR; Karruli, A; Maraolo, AE; Mikulska, MK; Moriello, NS; Palmiero, G; Paradiso, L; Sordella, F; Tascini, C; Tiseo, G; Vena, A; Viale, P; Vozza, A | 1 |
| Andini, R; De Gregorio, F; Durante-Mangoni, E; Esitini, D; Gallo, R; Iossa, D; Karruli, A; Marrazzo, T; Moretto, SM; Salemme, A; Zampino, R | 1 |
| Cumper, C; Jones, M; Litherland, K; Richards, C; Smart, J | 1 |
41 review(s) available for cephalosporin c and ceftobiprole
| Article | Year |
|---|---|
New antibiotics for the treatment of severe staphylococcal infection in the critically ill patient.
Topics: Acetamides; Aminoglycosides; Anti-Bacterial Agents; Cephalosporins; Clinical Trials as Topic; Critical Illness; Daptomycin; Drug Resistance, Multiple, Bacterial; Glycopeptides; Humans; Linezolid; Lipoglycopeptides; Methicillin Resistance; Minocycline; Oxazolidinones; Staphylococcal Infections; Teicoplanin; Tigecycline; Virginiamycin | 2005 |
MRSA--the tip of the iceberg.
Topics: Anti-Bacterial Agents; beta-Lactams; Cephalosporins; Community-Acquired Infections; Gram-Positive Bacteria; Humans; Methicillin Resistance; Staphylococcal Infections; Staphylococcus aureus; Vancomycin; Vancomycin Resistance | 2006 |
Can beta-lactams be re-engineered to beat MRSA?
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Cephalosporins; Drug Design; Humans; Methicillin Resistance; Staphylococcal Infections; Staphylococcus aureus | 2006 |
Ceftobiprole: in-vivo profile of a bactericidal cephalosporin.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Cephalosporins; Disease Models, Animal; Drug Resistance, Bacterial; Humans; Mice; Rabbits; Rats | 2006 |
Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy.
Topics: Animals; beta-Lactams; Cephalosporins; Drugs, Investigational; Humans; Methicillin Resistance; Staphylococcal Infections; Sulfhydryl Compounds | 2007 |
Combating resistance in a challenging, changing environment.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Cephalosporins; Cross Infection; Humans; Methicillin Resistance; Staphylococcal Infections; Staphylococcus aureus | 2007 |
In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Humans; Methicillin Resistance; Microbial Sensitivity Tests; Staphylococcal Infections; Staphylococcus aureus | 2007 |
Clinical profile of ceftobiprole, a novel beta-lactam antibiotic.
Topics: Anti-Bacterial Agents; Cephalosporins; Clinical Trials as Topic; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Skin Diseases, Bacterial; Staphylococcal Infections; Staphylococcal Skin Infections | 2007 |
Ceftobiprole: a new option for treatment of skin and soft-tissue infections due to methicillin-resistant Staphylococcus aureus.
Topics: Cephalosporins; Humans; Methicillin Resistance; Soft Tissue Infections; Staphylococcal Infections; Staphylococcal Skin Infections; Staphylococcus aureus | 2008 |
New antimicrobial agents for the treatment of Gram-positive bacterial infections.
Topics: Acetamides; Anti-Infective Agents; Cephalosporins; Daptomycin; Glycopeptides; Gram-Positive Bacterial Infections; Linezolid; Minocycline; Oxazolidinones; Tigecycline; Virginiamycin | 2008 |
Pharmacokinetic and pharmacodynamic profile of ceftobiprole.
Topics: Anti-Bacterial Agents; Cephalosporins; Cross Infection; Humans; Monte Carlo Method; Pneumonia; Skin Diseases, Bacterial | 2008 |
The efficacy and safety of ceftobiprole in the treatment of complicated skin and skin structure infections: evidence from 2 clinical trials.
Topics: Cephalosporins; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Skin Diseases, Bacterial; Treatment Outcome | 2008 |
Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.
Topics: Anti-Bacterial Agents; Bacterial Infections; Cephalosporins; Drugs, Investigational; Humans; Methicillin Resistance; Microbial Sensitivity Tests; Staphylococcal Infections; Staphylococcus aureus | 2008 |
Health care-associated pneumonia: identification and initial management in the ED.
Topics: Acetamides; Age Distribution; Aged; Aged, 80 and over; Anti-Infective Agents; beta-Lactams; Cephalosporins; Cross Infection; Emergency Treatment; Ertapenem; Female; Humans; Length of Stay; Linezolid; Male; Microbial Sensitivity Tests; Middle Aged; Minocycline; Oxazolidinones; Patient Care Team; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Practice Guidelines as Topic; Respiration, Artificial; Risk Factors; Severity of Illness Index; Tigecycline | 2008 |
Antimicrobial agents in treatment of MRSA infections.
Topics: Acetamides; Anti-Bacterial Agents; Cephalosporins; Clindamycin; Community-Acquired Infections; Daptomycin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fluoroquinolones; Humans; Linezolid; Methicillin-Resistant Staphylococcus aureus; Minocycline; Oxazolidinones; Staphylococcal Infections; Teicoplanin; Tetracyclines; Tigecycline; Trimethoprim, Sulfamethoxazole Drug Combination; United States; Vancomycin | 2008 |
What's new and not so new on the antimicrobial horizon?
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Carbapenems; Cephalosporins; Doripenem; Drug Resistance, Multiple, Bacterial; Humans; Pyrimidines; Research | 2008 |
New antibiotics for healthcare-associated pneumonia.
Topics: Aminoglycosides; Anti-Bacterial Agents; Carbapenems; Ceftaroline; Cephalosporins; Cross Infection; Doripenem; Glycopeptides; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Pneumonia, Bacterial; Pseudomonas Infections; Pyrimidines; Staphylococcal Infections; Teicoplanin | 2009 |
Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA).
Topics: Anti-Bacterial Agents; Canada; Cephalosporins; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Methicillin-Resistant Staphylococcus aureus; Treatment Outcome; United States | 2009 |
Ceftobiprole: a new beta-lactam antibiotic.
Topics: Animals; Anti-Bacterial Agents; Cephalosporins; Clinical Trials as Topic; Diabetic Foot; Disease Models, Animal; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Penicillin-Binding Proteins; Staphylococcal Infections | 2009 |
Ceftobiprole: a new broad spectrum cephalosporin.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Cephalosporins; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Cross Infection; Drug Interactions; Enterococcus faecalis; Gram-Positive Bacterial Infections; Humans; Methicillin Resistance; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Treatment Outcome | 2009 |
Ceftobiprole: a new cephalosporin for the treatment of skin and skin structure infections.
Topics: Anti-Bacterial Agents; Cephalosporins; Clinical Trials, Phase III as Topic; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests; Multicenter Studies as Topic; Skin Diseases, Bacterial; Treatment Outcome | 2009 |
Microbiology of drugs for treating multiply drug-resistant Gram-positive bacteria.
Topics: Aminoglycosides; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gram-Positive Bacterial Infections; Humans; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Staphylococcal Infections; Teicoplanin; Vancomycin | 2009 |
[Update on antimicrobial chemotherapy].
Topics: Acetamides; Aminoglycosides; Anti-Infective Agents; beta-Lactams; Carbapenems; Cephalosporins; Daptomycin; Doripenem; Drug Resistance, Bacterial; Ertapenem; Fluoroquinolones; France; Humans; Linezolid; Lipoglycopeptides; Minocycline; Oxazolidinones; Penicillins; Pyrimidines; Teicoplanin; Tigecycline | 2010 |
New antimicrobial agents for methicillin-resistant Staphylococcus aureus.
Topics: Aminoglycosides; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Glycopeptides; Humans; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Pyrimidines; Staphylococcal Infections; Teicoplanin | 2009 |
Ceftobiprole: A novel, broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bone Diseases, Infectious; Cephalosporins; Drug Resistance, Bacterial; Endocarditis, Bacterial; Humans; Infusions, Intravenous; Methicillin-Resistant Staphylococcus aureus | 2010 |
Newer antibacterial agents and their potential role in cystic fibrosis pulmonary exacerbation management.
Topics: Achromobacter denitrificans; Anti-Bacterial Agents; Carbapenems; Cephalosporins; Cystic Fibrosis; Doripenem; Humans; Minocycline; Pneumonia, Bacterial; Pseudomonas aeruginosa; Staphylococcus aureus; Stenotrophomonas maltophilia; Tigecycline | 2010 |
What's new in the treatment of serious MRSA infection?
Topics: Acetamides; Anti-Bacterial Agents; Cephalosporins; Cost-Benefit Analysis; Drug Administration Routes; Drug Therapy, Combination; Glycopeptides; Humans; Linezolid; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Oxazolidinones; Severity of Illness Index; Skin Diseases, Bacterial; Staphylococcal Infections; Tetrazoles; Vancomycin | 2014 |
Ceftobiprole for the treatment of pneumonia: a European perspective.
Topics: Anti-Bacterial Agents; Cephalosporins; Community-Acquired Infections; Cross Infection; Europe; Humans; Pneumonia, Bacterial; Treatment Outcome | 2015 |
Pharmacokinetic drug evaluation of ceftobiprole for the treatment of MRSA.
Topics: Anti-Bacterial Agents; Cephalosporins; Community-Acquired Infections; Critical Illness; Cross Infection; Humans; Methicillin-Resistant Staphylococcus aureus; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Staphylococcal Infections | 2017 |
[New antibiotics - standstill or progress].
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Infections; Ceftaroline; Ceftazidime; Cephalosporins; Clinical Trials as Topic; Drug Approval; Drug Combinations; Drug Resistance, Multiple, Bacterial; Ephedrine; Humans; Macrolides; Methicillin-Resistant Staphylococcus aureus; Organophosphates; Oxazoles; Penicillanic Acid; Phenobarbital; Staphylococcal Infections; Tazobactam; Theophylline; Triazoles | 2017 |
Clinical cure with ceftriaxone versus ceftaroline or ceftobiprole in the treatment of staphylococcal pneumonia: a systematic review and meta-analysis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Ceftaroline; Ceftriaxone; Cephalosporins; Child; Child, Preschool; Female; Humans; Male; Middle Aged; Pneumonia, Staphylococcal; Randomized Controlled Trials as Topic; Staphylococcus aureus; Treatment Outcome; Young Adult | 2019 |
Mechanisms of action and antimicrobial activity of ceftobiprole.
Topics: Aminoacyltransferases; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Community-Acquired Infections; Endopeptidases; Enterobacteriaceae; Enterococcus; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Methicillin-Resistant Staphylococcus aureus; Penicillin Resistance; Penicillin-Binding Proteins; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Streptococcus pneumoniae | 2019 |
Ceftobiprole: pharmacokinetics and PK/PD profile.
Topics: Age Factors; Anti-Bacterial Agents; Area Under Curve; Cephalosporins; Creatinine; Critical Illness; Extracellular Matrix; Half-Life; Humans; Infusions, Intravenous; Kidney; Monte Carlo Method; Obesity; Prodrugs; Renal Insufficiency; Renal Replacement Therapy | 2019 |
Ceftobiprole for the treatment of pneumonia.
Topics: Anti-Bacterial Agents; Cephalosporins; Clinical Trials as Topic; Community-Acquired Infections; Critical Illness; Cross Infection; Drug Administration Schedule; Humans; Pneumonia, Bacterial; Renal Insufficiency | 2019 |
Ceftobripole: Experience in staphylococcal bacteremia.
Topics: Anti-Bacterial Agents; Bacteremia; Cephalosporins; Daptomycin; Drug Therapy, Combination; Humans; Methicillin-Resistant Staphylococcus aureus; Pseudomonas aeruginosa; Staphylococcal Infections; Staphylococcus; Staphylococcus aureus | 2019 |
Possible clinical indications of ceftobiprole.
Topics: Anti-Bacterial Agents; Bacterial Infections; Catheter-Related Infections; Cephalosporins; Cross Infection; Diabetic Foot; Fever of Unknown Origin; Humans; Inpatients; Pneumonia, Bacterial; Skin Diseases, Bacterial; Soft Tissue Infections | 2019 |
Safety and tolerability of ceftobiprole.
Topics: Administration, Intravenous; Anti-Bacterial Agents; Cephalosporins; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Community-Acquired Infections; Cross Infection; Humans; Methicillin-Resistant Staphylococcus aureus; Neutropenia; Pneumonia, Bacterial; Pseudomonas aeruginosa; Streptococcus pneumoniae | 2019 |
Clinical efficacy and safety of ceftobiprole in the treatment of acute bacterial skin and skin structure infection: a systematic review and meta-analysis of randomized controlled trials.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Humans; Randomized Controlled Trials as Topic; Skin Diseases, Infectious; Treatment Outcome | 2022 |
Ceftobiprole: a clinical view.
Topics: Animals; Anti-Bacterial Agents; Cephalosporins; Endocarditis, Bacterial; Gram-Positive Bacteria | 2021 |
Clinical evidence supporting ceftaroline fosamil and ceftobiprole for complicated skin and soft tissue infections.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Soft Tissue Infections; Staphylococcal Infections | 2023 |
Ceftobiprole medocaril for the treatment of pneumonia.
Topics: Anti-Bacterial Agents; Cephalosporins; Child; Gram-Negative Bacteria; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Pneumonia; Staphylococcus aureus; Streptococcus pneumoniae | 2023 |
14 trial(s) available for cephalosporin c and ceftobiprole
| Article | Year |
|---|---|
Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers.
Topics: Adult; Area Under Curve; Cephalosporins; Chromatography, Liquid; Dose-Response Relationship, Drug; Double-Blind Method; Half-Life; Humans; Infusions, Intravenous; Male; Mass Spectrometry | 2004 |
Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers.
Topics: Adult; Area Under Curve; Cephalosporins; Chromatography, Liquid; Double-Blind Method; Half-Life; Humans; Infusions, Intravenous; Male; Mass Spectrometry; Molecular Weight | 2004 |
The efficacy and safety of ceftobiprole in the treatment of complicated skin and skin structure infections: evidence from 2 clinical trials.
Topics: Cephalosporins; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Skin Diseases, Bacterial; Treatment Outcome | 2008 |
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
Topics: Anti-Bacterial Agents; Cephalosporins; Enterobacteriaceae; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Skin Diseases, Bacterial; Staphylococcus | 2008 |
Molecular characterisation of meticillin-resistant Staphylococcus aureus isolates from two ceftobiprole Phase 3 complicated skin and skin-structure infection clinical trials.
Topics: Anti-Bacterial Agents; Bacterial Typing Techniques; Cephalosporins; Cluster Analysis; DNA Fingerprinting; DNA, Bacterial; Europe; Genotype; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Staphylococcal Skin Infections; United States | 2009 |
Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis.
Topics: Adipose Tissue; Adult; Anti-Bacterial Agents; Cephalosporins; Humans; Infusions, Intravenous; Male; Microdialysis; Muscle, Skeletal; Young Adult | 2009 |
Exposure to ceftobiprole is associated with microbiological eradication and clinical cure in patients with nosocomial pneumonia.
Topics: Anti-Bacterial Agents; Cephalosporins; Double-Blind Method; Humans; Logistic Models; Pneumonia | 2014 |
Pharmacokinetics and Target Attainment of Ceftobiprole in Asian and Non-Asian Subjects.
Topics: Adult; Aged; Anti-Bacterial Agents; Area Under Curve; Asian People; Cephalosporins; Female; Humans; Infusions, Intravenous; Male; Middle Aged; White People; Young Adult | 2018 |
Early improvement in severely ill patients with pneumonia treated with ceftobiprole: a retrospective analysis of two major trials.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Ceftazidime; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Cross Infection; Female; Humans; Linezolid; Male; Middle Aged; Pneumonia; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2019 |
Ceftobiprole versus daptomycin in
Topics: Adult; Bacteremia; Cephalosporins; Clinical Trials as Topic; Daptomycin; Double-Blind Method; Drug Resistance, Multiple, Bacterial; Female; Hospitalization; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Staphylococcal Infections; Staphylococcus aureus; Treatment Failure; Treatment Outcome; Young Adult | 2020 |
Ceftobiprole Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Results of a Phase 3, Randomized, Double-blind Trial (TARGET).
Topics: Anti-Bacterial Agents; Aztreonam; Cephalosporins; Double-Blind Method; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Methicillin-Resistant Staphylococcus aureus; Skin Diseases, Bacterial; Treatment Outcome; Vancomycin | 2021 |
A Phase 3, Randomized, Investigator-blinded Trial Comparing Ceftobiprole With a Standard-of-care Cephalosporin, With or Without Vancomycin, for the Treatment of Pneumonia in Pediatric Patients.
Topics: Adolescent; Anti-Bacterial Agents; Cephalosporins; Child; Child, Preschool; Cross Infection; Female; Hospitalization; Humans; Infant; Infusions, Intravenous; Male; Pneumonia, Bacterial; Treatment Outcome; Vancomycin | 2021 |
A
Topics: Asia, Eastern; Cephalosporins; Community-Acquired Infections; Cross Infection; Humans; Pneumonia, Bacterial | 2021 |
Pharmacokinetics and Safety of Ceftobiprole in Pediatric Patients.
Topics: Administration, Intravenous; Adolescent; Anti-Bacterial Agents; Cephalosporins; Child; Child, Preschool; Community-Acquired Infections; Cross Infection; Data Analysis; Female; Humans; Infant; Infant, Newborn; Male; Microbial Sensitivity Tests; Pneumonia | 2021 |
142 other study(ies) available for cephalosporin c and ceftobiprole
| Article | Year |
|---|---|
In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci.
Topics: Abscess; Animals; Bacterial Proteins; beta-Lactamases; Carrier Proteins; Cephalosporins; Disease Models, Animal; Enzyme Stability; Hexosyltransferases; Methicillin Resistance; Mice; Microbial Sensitivity Tests; Muramoylpentapeptide Carboxypeptidase; Penicillin-Binding Proteins; Peptidyl Transferases; Sepsis; Staphylococcus aureus; Substrate Specificity | 2001 |
BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis.
Topics: Animals; Bacterial Proteins; Carrier Proteins; Cephalosporins; Drug Stability; Endocarditis, Bacterial; Hexosyltransferases; Methicillin Resistance; Microbial Sensitivity Tests; Muramoylpentapeptide Carboxypeptidase; Penicillin-Binding Proteins; Penicillinase; Peptidyl Transferases; Rats; Staphylococcal Infections; Staphylococcus aureus; Time Factors; Treatment Outcome | 2002 |
In vitro activities of BAL9141, a novel broad-spectrum pyrrolidinone cephalosporin, against gram-negative nonfermenters.
Topics: Cephalosporins; Fermentation; Glucose; Gram-Negative Bacteria; Microbial Sensitivity Tests | 2002 |
BAL 9141, a new broad-spectrum pyrrolidinone cephalosporin: activity against clinically significant anaerobes in comparison with 10 other antimicrobials.
Topics: Bacteria, Anaerobic; Cephalosporins; Drug Resistance, Bacterial; Lactams; Penicillins; Thienamycins | 2002 |
In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci.
Topics: Cephalosporins; Drug Evaluation, Preclinical; Humans; Microbial Sensitivity Tests; Oxacillin; Penicillin Resistance; Staphylococcus | 2002 |
Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococci.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Synergism; Enterococcus; Humans; Microbial Sensitivity Tests; Staphylococcus aureus; Streptococcus | 2003 |
In vitro activity of BAL9141 against clinical isolates of gram-negative bacteria.
Topics: Cephalosporins; Drug Resistance, Bacterial; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Sampling Studies; Sensitivity and Specificity | 2004 |
Efficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumonia.
Topics: Animals; Ceftriaxone; Cephalosporin Resistance; Cephalosporins; Female; Injections, Subcutaneous; Leukopenia; Lung; Mice; Microbial Sensitivity Tests; Pneumonia, Pneumococcal; Prodrugs; Streptococcus pneumoniae; Survival Analysis | 2004 |
Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141.
Topics: Anti-Infective Agents; Area Under Curve; Cephalosporins; Humans; Microbial Sensitivity Tests; Models, Statistical; Monte Carlo Method | 2004 |
Superbugs and Superdrugs: a focus on antibacterials--6th annual SMi conference.
Topics: Amidohydrolases; Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Cephalosporins; Clinical Trials as Topic; Daptomycin; Drug Design; Drug Evaluation, Preclinical; Drug Resistance; Drug Resistance, Multiple, Bacterial; Humans; Ketolides; Marketing; Mice; Protein Synthesis Inhibitors; Ribosomes; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2004 |
Quality control guidelines for BAL9141 (Ro 63-9141), an investigational cephalosporin, when reference MIC and standardized disk diffusion susceptibility test methods are used.
Topics: Cephalosporins; Diffusion; Microbial Sensitivity Tests; Quality Control | 2004 |
Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates.
Topics: Cephalosporins; Drug Resistance, Bacterial; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Male; Microbial Sensitivity Tests; Penicillin Resistance; Sensitivity and Specificity | 2004 |
Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus.
Topics: Animals; Aortic Valve; Cephalosporins; Disease Models, Animal; Endocarditis, Bacterial; Heart Valve Diseases; Methicillin Resistance; Microbial Sensitivity Tests; Rabbits; Staphylococcal Infections; Staphylococcus aureus; Vancomycin | 2005 |
Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin.
Topics: Cephalosporins; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Fluoroquinolones; Microbial Sensitivity Tests; Streptococcus pneumoniae | 2005 |
Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
Topics: Animals; Cephalosporins; Foreign Bodies; Methicillin Resistance; Microbial Sensitivity Tests; Mutation; Rats; Rats, Wistar; Staphylococcal Infections; Staphylococcus aureus; Vancomycin | 2005 |
Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Bacterial; Gram-Positive Bacteria; Microbial Sensitivity Tests; Staphylococcus aureus | 2005 |
Comparative in vitro activity of ceftobiprole against staphylococci displaying normal and small-colony variant phenotypes.
Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Cefuroxime; Cephalosporins; Fluoroquinolones; Genetic Variation; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Oxazolidinones; Phenotype; Quinolines; Staphylococcal Infections; Staphylococcus | 2005 |
Ceftobiprole medocaril (BAL5788) treatment of experimental Haemophilus influenzae, Enterobacter cloacae, and Klebsiella pneumoniae murine pneumonia.
Topics: Animals; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Bacterial; Enterobacter cloacae; Female; Haemophilus influenzae; Immunocompetence; Klebsiella pneumoniae; Mice; Models, Animal; Pneumonia, Bacterial; Statistics, Nonparametric; Tissue Distribution | 2006 |
Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Azithromycin; beta-Lactamases; Cefpodoxime; Ceftizoxime; Ceftriaxone; Cephalosporins; Colony Count, Microbial; Drug Resistance, Bacterial; Fluoroquinolones; Haemophilus influenzae; Humans; In Vitro Techniques; Ketolides; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Quinolines; Selection, Genetic | 2006 |
Activities of ceftobiprole and other beta-lactams against Streptococcus pneumoniae clinical isolates from the United States with defined substitutions in penicillin-binding proteins PBP 1a, PBP 2b, and PBP 2x.
Topics: Amino Acid Motifs; Aminoacyltransferases; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactams; Cephalosporins; Humans; Microbial Sensitivity Tests; Mutation; Penicillin-Binding Proteins; Peptidyl Transferases; Streptococcus pneumoniae; United States | 2006 |
In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals.
Topics: Anti-Bacterial Agents; Belgium; Cephalosporins; Daptomycin; Drug Resistance, Bacterial; Exotoxins; Genes, Bacterial; Hospitals; Humans; In Vitro Techniques; Methicillin Resistance; Microbial Sensitivity Tests; Minocycline; Molecular Epidemiology; Staphylococcal Infections; Staphylococcus aureus; Tigecycline | 2006 |
In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections.
Topics: Anti-Bacterial Agents; Bacteria, Aerobic; Bacteria, Anaerobic; Cephalosporins; Diabetic Foot; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests | 2006 |
Postantibiotic effect of ceftobiprole against 12 Gram-positive organisms.
Topics: Anti-Bacterial Agents; beta-Lactams; Cephalosporins; Enterococcus faecalis; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Staphylococcus aureus; Streptococcus pneumoniae | 2006 |
Interscience conference on antimicrobial agents and chemotherapy--46th annual meeting. Release of data for Dc-159a, and other agents. 27-30 September 2006, San Francisco, CA, USA.
Topics: Animals; Anti-Infective Agents; Carbapenems; Cephalosporins; Drugs, Investigational; Estrogen Receptor Modulators; Fluoroquinolones; Humans; Naphthols; Societies, Scientific; United States | 2006 |
Antianaerobe activity of ceftobiprole, a new broad-spectrum cephalosporin.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Cephalosporins; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests | 2007 |
Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Cephalosporins; Clinical Trials, Phase II as Topic; Computer Simulation; Creatine; Drug Administration Schedule; Drug Therapy, Computer-Assisted; Female; Gram-Negative Bacteria; Humans; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Population; Probability; Staphylococcus; Treatment Outcome | 2007 |
Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including beta-lactamase-producing and vancomycin-resistant isolates.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Drug Synergism; Enterococcus faecalis; Gentamicins; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests; Streptomycin; Vancomycin Resistance | 2007 |
Identification and phenotypic characterization of a beta-lactam-dependent, methicillin-resistant Staphylococcus aureus strain.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactams; Cephalosporins; Chromosomes, Bacterial; DNA-Binding Proteins; DNA, Bacterial; Electrophoresis, Gel, Pulsed-Field; Gene Expression Regulation, Bacterial; Methicillin Resistance; Microbial Sensitivity Tests; Molecular Sequence Data; Oligonucleotide Array Sequence Analysis; Phenotype; Reverse Transcriptase Polymerase Chain Reaction; Selection, Genetic; Sequence Analysis, DNA; Sequence Homology, Amino Acid; Staphylococcus aureus; Transcription, Genetic | 2007 |
Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
Topics: Bacterial Proteins; Cephalosporins; Escherichia coli Proteins; Gram-Negative Bacteria; Inhibitory Concentration 50; Microbial Sensitivity Tests; Penicillin-Binding Proteins; Pseudomonas aeruginosa; Staphylococcus aureus; Streptococcus pneumoniae | 2007 |
Redesigning beta-lactams to combat resistance: summary and conclusions.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactam Resistance; Cephalosporins; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Methicillin Resistance; Staphylococcal Infections; Staphylococcus aureus | 2007 |
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
Topics: Anti-Bacterial Agents; Bacteria; beta-Lactamases; Cefepime; Ceftazidime; Cephalosporins; Hydrolysis; Kinetics; Microbial Sensitivity Tests; Spectrophotometry, Ultraviolet | 2007 |
Activity of ceftobiprole against community-associated methicillin-resistant Staphylococcus aureus isolates recently recovered from US military trainees.
Topics: Anti-Bacterial Agents; Cephalosporins; Community-Acquired Infections; Humans; Methicillin; Methicillin Resistance; Microbial Sensitivity Tests; Military Personnel; Staphylococcal Infections; Staphylococcus aureus; United States | 2007 |
Activity of ceftobiprole compared with those of other agents against Staphylococcus aureus strains with different resistotypes by time-kill analysis.
Topics: Anti-Bacterial Agents; Cephalosporins; Humans; Microbial Sensitivity Tests; Microbial Viability; Staphylococcal Infections; Staphylococcus aureus; Time Factors | 2008 |
Update on prevalence and treatment of methicillin-resistant Staphylococcus aureus infections.
Topics: Acetamides; Aminoglycosides; Anti-Bacterial Agents; Cephalosporins; Clindamycin; Daptomycin; Doxycycline; Folic Acid Antagonists; Global Health; Glycopeptides; Humans; Linezolid; Lipoglycopeptides; Methicillin; Methicillin Resistance; Minocycline; Oxazolidinones; Prevalence; Staphylococcal Infections; Staphylococcus aureus; Sulfamethoxazole; Teicoplanin; Tigecycline; Trimethoprim; Vancomycin | 2007 |
In vitro activity of ceftobiprole against Burkholderia pseudomallei.
Topics: Burkholderia pseudomallei; Cephalosporins; Humans; Microbial Sensitivity Tests | 2008 |
In vitro activity of ceftobiprole against coagulase-negative staphylococci isolated in the USA.
Topics: Anti-Bacterial Agents; Cephalosporins; Coagulase; Microbial Sensitivity Tests; Staphylococcal Infections; Staphylococcus; United States | 2008 |
In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin.
Topics: Anti-Bacterial Agents; Cephalosporins; Europe; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Methicillin Resistance; Microbial Sensitivity Tests; Staphylococcus aureus | 2008 |
In vitro selection and characterization of ceftobiprole-resistant methicillin-resistant Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Cephalosporins; Culture Media; Drug Resistance, Bacterial; Humans; Methicillin Resistance; Models, Molecular; Mutation; Penicillin-Binding Proteins; Selection, Genetic; Serial Passage; Staphylococcus aureus | 2008 |
Ceftobiprole: breaking therapeutic dogmas of the beta-lactam class.
Topics: Anti-Bacterial Agents; Bacterial Infections; Cephalosporins; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests | 2008 |
Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).
Topics: Anti-Bacterial Agents; Bacterial Infections; Cephalosporins; Europe; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Latin America; Microbial Sensitivity Tests; North America | 2008 |
In vitro activity of ceftobiprole against clinical isolates of Pseudomonas aeruginosa obtained from Canadian intensive care unit (ICU) patients as part of the CAN-ICU Study.
Topics: Anti-Bacterial Agents; Canada; Cephalosporins; Cross Infection; Humans; Intensive Care Units; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2008 |
Pharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strains.
Topics: Animals; Anti-Bacterial Agents; Cephalosporins; Community-Acquired Infections; Cross Infection; Disease Models, Animal; Drug Resistance, Bacterial; Female; Humans; Methicillin Resistance; Mice; Mice, Inbred BALB C; Phenotype; Pneumonia, Staphylococcal; Staphylococcus aureus | 2008 |
Comparative study of the susceptibilities of major epidemic clones of methicillin-resistant Staphylococcus aureus to oxacillin and to the new broad-spectrum cephalosporin ceftobiprole.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Cephalosporins; Chromatography, High Pressure Liquid; Humans; Methicillin Resistance; Microbial Sensitivity Tests; Oxacillin; Staphylococcal Infections; Staphylococcus aureus; Vancomycin | 2008 |
Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus.
Topics: Acetamides; Anti-Bacterial Agents; Cephalosporins; Community-Acquired Infections; Cross Infection; Daptomycin; Drug Synergism; Humans; Linezolid; Methicillin Resistance; Microbial Sensitivity Tests; Oxazolidinones; Staphylococcal Infections; Staphylococcus aureus; Vancomycin | 2008 |
In vitro activity of ceftobiprole, linezolid, tigecycline, and 23 other antimicrobial agents against Staphylococcus aureus isolates in China.
Topics: Acetamides; Anti-Bacterial Agents; Cephalosporins; China; Humans; Linezolid; Methicillin; Methicillin Resistance; Microbial Sensitivity Tests; Minocycline; Oxazolidinones; Prevalence; Staphylococcal Infections; Staphylococcus aureus; Tigecycline | 2008 |
In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Cephalosporin Resistance; Cephalosporins; Disease Models, Animal; Dose-Response Relationship, Drug; Enterobacteriaceae Infections; Extremities; Female; Gram-Negative Bacterial Infections; Lung Diseases; Methicillin Resistance; Mice; Mice, Inbred ICR; Neutropenia; Penicillin Resistance; Pneumococcal Infections; Staphylococcal Infections; Staphylococcus aureus | 2008 |
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Incompatibility; Glucose; Humans; Infusions, Intravenous; Isotonic Solutions; Particle Size; Pharmaceutical Vehicles; Ringer's Solution; Sodium Chloride; Time Factors | 2008 |
Population pharmacokinetic analysis of ceftobiprole for treatment of complicated skin and skin structure infections.
Topics: Anti-Bacterial Agents; Case-Control Studies; Cephalosporins; Clinical Trials, Phase III as Topic; Computer Simulation; Creatinine; Humans; Infusions, Intravenous; Kidney Function Tests; Male; Metabolic Clearance Rate; Microbial Sensitivity Tests; Models, Biological; Population; Skin Diseases, Infectious; Software | 2009 |
Activities of ceftobiprole and other cephalosporins against extracellular and intracellular (THP-1 macrophages and keratinocytes) forms of methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Cell Line; Cephalosporins; Dose-Response Relationship, Drug; Humans; Hydrogen-Ion Concentration; Keratinocytes; Macrophages; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Phagocytosis; Ribonucleoproteins; Saccharomyces cerevisiae Proteins; Staphylococcus aureus | 2009 |
In vitro activity of ceftobiprole against Acinetobacter baumannii clinical isolates.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Gene Expression; Genes, Bacterial; Humans; Intensive Care Units; Microbial Sensitivity Tests; Pneumonia, Ventilator-Associated | 2009 |
Effect of MexXY overexpression on ceftobiprole susceptibility in Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Cefepime; Cephalosporins; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Gene Expression; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Reverse Transcriptase Polymerase Chain Reaction | 2009 |
Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole.
Topics: Adult; Animals; Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Cephalosporins; Disease Models, Animal; Epithelium; Female; Humans; Mice; Monte Carlo Method; Pneumonia, Staphylococcal | 2009 |
Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model
Topics: Anti-Bacterial Agents; Cephalosporins; Colony Count, Microbial; Community-Acquired Infections; Cross Infection; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Microbial Viability; Staphylococcal Infections; Staphylococcus aureus; Vancomycin; Vancomycin Resistance | 2009 |
Pharmacodynamic profiling of ceftobiprole for treatment of complicated skin and skin structure infections.
Topics: Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Female; Humans; Male; Microbial Sensitivity Tests; Skin Diseases, Infectious; Treatment Outcome; Vancomycin | 2009 |
Overproduction of K1 enzyme in Klebsiella oxytoca clinical isolates against ceftazidime, cefepime and ceftobiprole.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cefepime; Ceftazidime; Cephalosporins; Humans; Klebsiella oxytoca; Microbial Sensitivity Tests | 2009 |
In vitro activity of ceftaroline, ceftobiprole and cethromycin against clinical isolates of Streptococcus pneumoniae collected from across Canada between 2003 and 2008.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Canada; Ceftaroline; Cephalosporins; Child; Child, Preschool; Female; Humans; Infant; Infant, Newborn; Ketolides; Male; Microbial Sensitivity Tests; Middle Aged; Streptococcal Infections; Streptococcus pneumoniae; Young Adult | 2009 |
Antimicrobial development in the era of emerging resistance.
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Bacteria; beta-Lactams; Cephalosporins; Drug Approval; Drug Resistance, Bacterial; Glycopeptides; Humans; Lipoglycopeptides; Pyrimidines; Skin Diseases, Bacterial; Skin Diseases, Viral; Teicoplanin; United States; United States Food and Drug Administration | 2009 |
In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Bacterial Proteins; beta-Lactamases; Cephalosporins; Colony Count, Microbial; Dose-Response Relationship, Drug; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Half-Life; Immunocompromised Host; Methicillin-Resistant Staphylococcus aureus; Mice; Mice, Hairless; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Skin Diseases, Infectious; Staphylococcal Infections; Staphylococcus aureus | 2010 |
Ceftobiprole is superior to vancomycin, daptomycin, and linezolid for treatment of experimental endocarditis in rabbits caused by methicillin-resistant Staphylococcus aureus.
Topics: Acetamides; Animals; Anti-Bacterial Agents; Cephalosporins; Chromatography, High Pressure Liquid; Daptomycin; Disease Models, Animal; Endocarditis, Bacterial; Linezolid; Methicillin-Resistant Staphylococcus aureus; Oxazolidinones; Rabbits; Random Allocation; Vancomycin | 2010 |
Interaction of ceftobiprole with the low-affinity PBP 5 of Enterococcus faecium.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Cephalosporins; Enterococcus faecium; Microbial Sensitivity Tests; Penicillin G; Protein Binding | 2010 |
Effects of ceftobiprole and oxacillin on mecA expression in methicillin-resistant Staphylococcus aureus clinical isolates.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Cephalosporins; Gene Expression Regulation, Bacterial; Methicillin-Resistant Staphylococcus aureus; Oxacillin; Penicillin-Binding Proteins; Polymerase Chain Reaction | 2010 |
In vitro bactericidal activity of ceftobiprole against hospital- and community-associated methicillin-resistant Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Bacterial Typing Techniques; Cephalosporins; Colony Count, Microbial; Community-Acquired Infections; Cross Infection; DNA Fingerprinting; DNA, Bacterial; Electrophoresis, Gel, Pulsed-Field; Genotype; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Microbial Viability; Staphylococcal Infections | 2010 |
In vitro activity of ceftobiprole against Gram-positive and Gram-negative bacteria isolated from humans and animals.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Cephalosporins; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests | 2010 |
Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
Topics: Acetamides; Aminoglycosides; Anti-Bacterial Agents; Cephalosporins; Daptomycin; Drug Resistance, Bacterial; Drug Synergism; Linezolid; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Oxazolidinones; Sisomicin; Time Factors | 2010 |
Ceftobiprole: Farewell or just a delay?
Topics: Anti-Bacterial Agents; Bacterial Infections; Cephalosporins; Drug Approval; Humans; Methicillin-Resistant Staphylococcus aureus; Pseudomonas aeruginosa; United States; United States Food and Drug Administration; Vancomycin | 2010 |
Comparative in vitro activity of ceftobiprole against Gram-positive cocci.
Topics: Anti-Bacterial Agents; Cephalosporins; Coagulase; Hemolysin Proteins; Humans; Macrolides; Methicillin Resistance; Microbial Sensitivity Tests; Penicillin Resistance; Staphylococcus aureus; Streptococcus agalactiae; Streptococcus pneumoniae; Streptococcus pyogenes | 2010 |
Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Cefepime; Ceftazidime; Cephalosporins; Microbial Sensitivity Tests; Mutation; Pseudomonas aeruginosa | 2010 |
Affinity of ceftobiprole for penicillin-binding protein 2b in Streptococcus pneumoniae strains with various susceptibilities to penicillin.
Topics: Anti-Bacterial Agents; Ceftriaxone; Cephalosporins; Inhibitory Concentration 50; Microbial Sensitivity Tests; Penicillin-Binding Proteins; Penicillins; Protein Binding; Streptococcus pneumoniae | 2010 |
In vitro activity of ceftobiprole against meticillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA).
Topics: Anti-Bacterial Agents; Bacterial Typing Techniques; Cephalosporins; Daptomycin; DNA Fingerprinting; DNA, Bacterial; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Humans; Microbial Sensitivity Tests; Staphylococcal Infections; Staphylococcus aureus | 2010 |
Effect of ceftobiprole on the normal human intestinal microflora.
Topics: Adult; Anti-Bacterial Agents; Bacteria; Cephalosporins; Colony Count, Microbial; Feces; Female; Fungi; Gastrointestinal Tract; Human Experimentation; Humans; Male; Metagenome; Plasma | 2010 |
Comparative activity of ceftobiprole against Gram-positive and Gram-negative isolates from Europe and the Middle East: the CLASS study.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Europe; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests; Middle East | 2011 |
Ceftobiprole associated agranulocytosis after drug rash with eosinophilia and systemic symptoms induced by vancomycin and rifampicin.
Topics: Aged; Agranulocytosis; Anti-Bacterial Agents; Cephalosporins; Drug Eruptions; Drug Therapy, Combination; Eosinophilia; Female; Humans; Rifampin; Syndrome; Vancomycin | 2011 |
In vitro antibacterial activity of ceftobiprole against clinical isolates from French teaching hospitals: proposition of zone diameter breakpoints.
Topics: Anti-Bacterial Agents; Cephalosporins; Disk Diffusion Antimicrobial Tests; Drug Resistance, Bacterial; Enterobacteriaceae; France; Hospitals, Teaching; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Streptococcaceae | 2011 |
Effect of ceftobiprole treatment on growth of and toxin production by Clostridium difficile in cecal contents of mice.
Topics: Animals; Anti-Bacterial Agents; Cecum; Cephalosporins; Clostridioides difficile; Female; Mice; Microbial Sensitivity Tests | 2011 |
In vitro activity of ceftobiprole against frequently encountered aerobic and facultative Gram-positive and Gram-negative bacterial pathogens: results of the CANWARD 2007-2009 study.
Topics: Anti-Bacterial Agents; Canada; Cephalosporins; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests | 2011 |
Microtiter plate-based assay for inhibitors of penicillin-binding protein 2a from methicillin-resistant Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Discovery; Methicillin-Resistant Staphylococcus aureus; Penicillin-Binding Proteins | 2011 |
In vitro activities of ceftobiprole combined with amikacin or levofloxacin against Pseudomonas aeruginosa: evidence of a synergistic effect using time-kill methodology.
Topics: Amikacin; Anti-Bacterial Agents; Cephalosporins; Drug Synergism; Drug Therapy, Combination; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa; Stem Cells; Time Factors | 2011 |
In vivo synergism of ceftobiprole and vancomycin against experimental endocarditis due to vancomycin-intermediate Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Cephalosporins; Drug Synergism; Endocarditis; Female; Microbial Sensitivity Tests; Rats; Rats, Wistar; Staphylococcus aureus; Vancomycin | 2011 |
In vitro activity of ceftobiprole and seven other antimicrobial agents against invasive Streptococcus pneumoniae isolates in Spain.
Topics: Adult; Anti-Infective Agents; Cephalosporins; Genotype; Humans; Microbial Sensitivity Tests; Pneumococcal Infections; Serotyping; Spain; Streptococcus pneumoniae | 2011 |
Efficacy of ceftobiprole Medocaril against Enterococcus faecalis in a murine urinary tract infection model.
Topics: Animals; Anti-Bacterial Agents; Cephalosporins; Enterococcus faecalis; Mice; Urinary Tract Infections | 2012 |
What's behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance.
Topics: Anti-Bacterial Agents; Carbapenems; Cephalosporins; Critical Illness; Cross Infection; Doripenem; Humans; Kidney; Metabolic Clearance Rate; Pneumonia; Pneumonia, Ventilator-Associated; Randomized Controlled Trials as Topic | 2012 |
Activity of ceftobiprole against Streptococcus pneumoniae isolates exhibiting high-level resistance to ceftriaxone.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactams; Ceftriaxone; Cephalosporins; Genotype; Humans; Microbial Sensitivity Tests; Penicillin-Binding Proteins; Penicillins; Peptide Synthases; Sequence Analysis, DNA; Streptococcus pneumoniae | 2012 |
Structural insights into the anti-methicillin-resistant Staphylococcus aureus (MRSA) activity of ceftobiprole.
Topics: Anti-Bacterial Agents; beta-Lactams; Calorimetry, Differential Scanning; Catalytic Domain; Cephalosporins; Crystallography, X-Ray; Enzyme Inhibitors; Kinetics; Methicillin-Resistant Staphylococcus aureus; Models, Molecular; Molecular Conformation; Protein Binding; Protein Conformation; Staphylococcal Infections; Staphylococcus aureus | 2012 |
Ceftobiprole efficacy in vitro against Panton-Valentine leukocidin production and in vivo against community-associated methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits.
Topics: Animals; Anti-Bacterial Agents; Bacterial Toxins; Cephalosporins; Colony Count, Microbial; Community-Acquired Infections; Exotoxins; Female; Leukocidins; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Mutation; Osteomyelitis; Rabbits; Rifampin | 2012 |
Inoculum effects of ceftobiprole, daptomycin, linezolid, and vancomycin with Staphylococcus aureus and Streptococcus pneumoniae at inocula of 10(5) and 10(7) CFU injected into opposite thighs of neutropenic mice.
Topics: Acetamides; Animals; Anti-Bacterial Agents; Cephalosporins; Colony Count, Microbial; Daptomycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Injections, Subcutaneous; Linezolid; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Neutropenia; Oxazolidinones; Pneumococcal Infections; Staphylococcal Infections; Staphylococcus aureus; Streptococcus pneumoniae; Thigh; Vancomycin | 2013 |
Monte Carlo simulations based on phase 1 studies predict target attainment of ceftobiprole in nosocomial pneumonia patients: a validation study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cephalosporins; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Cross Infection; Drug Dosage Calculations; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Pneumonia, Bacterial | 2013 |
Analysis of the small RNA transcriptional response in multidrug-resistant Staphylococcus aureus after antimicrobial exposure.
Topics: Acetamides; Anti-Bacterial Agents; Cephalosporins; Linezolid; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Minocycline; Oxazolidinones; Protein Biosynthesis; RNA, Bacterial; RNA, Messenger; RNA, Small Untranslated; Sequence Analysis, RNA; Tigecycline; Transcription, Genetic; Vancomycin | 2013 |
Trends in the susceptibility of methicillin-resistant Staphylococcus aureus to nine antimicrobial agents, including ceftobiprole, nemonoxacin, and tyrothricin: results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) study, 2006-2010.
Topics: Anti-Bacterial Agents; Cephalosporins; Epidemiological Monitoring; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Quinolones; Staphylococcal Infections; Taiwan; Tyrothricin | 2014 |
Application of pharmacokinetic/pharmacodynamic modelling and simulation for the prediction of target attainment of ceftobiprole against meticillin-resistant Staphylococcus aureus using minimum inhibitory concentration and time-kill curve based approaches.
Topics: Anti-Bacterial Agents; Cephalosporins; Healthy Volunteers; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Monte Carlo Method; Muscle, Skeletal; Plasma; Staphylococcal Infections; Subcutaneous Fat; Time Factors | 2014 |
Evaluation of the in vitro activities of ceftobiprole and comparators in staphylococcal colony or microtitre plate biofilm assays.
Topics: Anti-Bacterial Agents; Biofilms; Cephalosporins; Colony Count, Microbial; Humans; Microbial Sensitivity Tests; Staphylococcus aureus; Staphylococcus epidermidis; Time Factors | 2014 |
Molecular dynamics and molecular docking studies on E166A point mutant, R274N/R276N double mutant, and E166A/R274N/R276N triple mutant forms of class A β-lactamases.
Topics: Alanine; Anti-Bacterial Agents; Asparagine; beta-Lactamases; Cefpirome; Cephalosporins; Humans; Hydrogen Bonding; Ligands; Molecular Docking Simulation; Molecular Dynamics Simulation; Mutation | 2014 |
Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit-isolated methicillin-resistant Staphylococcus aureus.
Topics: Acetamides; Anti-Bacterial Agents; Cephalosporins; Computer Simulation; Cross Infection; Daptomycin; Dose-Response Relationship, Drug; Humans; Intensive Care Units; Linezolid; Methicillin Resistance; Methicillin-Resistant Staphylococcus aureus; Minocycline; Models, Biological; Monte Carlo Method; Oxazolidinones; Staphylococcal Infections; Teicoplanin; Tigecycline; Vancomycin | 2014 |
Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types.
Topics: Acetamides; Anti-Bacterial Agents; Cephalosporins; Daptomycin; Linezolid; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Oxazolidinones; Staphylococcal Infections; Vancomycin | 2014 |
Molecular docking and molecular dynamics studies on β-lactamases and penicillin binding proteins.
Topics: Aminoacyltransferases; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Cephalosporins; Escherichia coli; Molecular Docking Simulation; Molecular Dynamics Simulation; Penicillin-Binding Proteins; Peptide Synthases; Protein Binding; Staphylococcus aureus; Streptococcus pneumoniae | 2014 |
Ceftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005 to 2010.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Cephalosporins; Europe; Humans; Israel; Microbial Sensitivity Tests; Public Health Surveillance; Reference Standards; Turkey | 2014 |
Potent synergy of ceftobiprole plus daptomycin against multiple strains of Staphylococcus aureus with various resistance phenotypes.
Topics: Anti-Bacterial Agents; Cephalosporins; Daptomycin; Drug Resistance, Multiple, Bacterial; Drug Synergism; Humans; Microbial Sensitivity Tests; Phenotype; Staphylococcus aureus | 2014 |
Quercetin 3-O-rutinoside mediated inhibition of PBP2a: computational and experimental evidence to its anti-MRSA activity.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Cephalosporins; Glucosides; Hydrogen Bonding; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Molecular Docking Simulation; Molecular Dynamics Simulation; Penicillin-Binding Proteins; Peptide Synthases; Protein Conformation; Quercetin | 2014 |
Ceftobiprole and ampicillin increase daptomycin susceptibility of daptomycin-susceptible and -resistant VRE.
Topics: Ampicillin; Cephalosporins; Daptomycin; Dose-Response Relationship, Drug; Drug Synergism; Enterococcus; Humans; Microbial Sensitivity Tests; Vancomycin Resistance | 2015 |
Rates of susceptibility of carbapenems, ceftobiprole, and colistin against clinically important bacteria collected from intensive care units in 2007: Results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART).
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Carbapenems; Cephalosporins; Colistin; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Humans; Intensive Care Units; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Surveys and Questionnaires; Taiwan | 2016 |
Ceftobiprole- and ceftaroline-resistant methicillin-resistant Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Drug Resistance, Multiple, Bacterial; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests | 2015 |
Genotypic Characterization of Methicillin-Resistant Staphylococcus aureus Recovered at Baseline from Phase 3 Pneumonia Clinical Trials for Ceftobiprole.
Topics: Anti-Bacterial Agents; Asia; Bacterial Toxins; Cephalosporins; Clinical Trials, Phase III as Topic; Community-Acquired Infections; Cross Infection; Europe; Exotoxins; Genotype; Humans; Leukocidins; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Multilocus Sequence Typing; North America; Pneumonia; South Africa; South America; Staphylococcal Infections | 2016 |
Missense mutations of PBP2a are associated with reduced susceptibility to ceftaroline and ceftobiprole in African MRSA.
Topics: Africa; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; Carrier State; Ceftaroline; Cephalosporins; Genotype; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Multilocus Sequence Typing; Mutation, Missense; Penicillin-Binding Proteins; Sequence Analysis, DNA; Staphylococcal Infections | 2016 |
The Recombinant Bacteriophage Endolysin HY-133 Exhibits In Vitro Activity against Different African Clonal Lineages of the Staphylococcus aureus Complex, Including Staphylococcus schweitzeri.
Topics: Africa; Anti-Bacterial Agents; beta-Lactam Resistance; Ceftaroline; Cephalosporins; Endopeptidases; Humans; Methicillin Resistance; Microbial Sensitivity Tests; Recombinant Proteins; Staphylococcal Infections; Staphylococcus; Staphylococcus aureus; Staphylococcus Phages | 2016 |
Meticillin-resistant Staphylococcus aureus endocarditis: first report of daptomycin plus ceftobiprole combination as salvage therapy.
Topics: Aged; Anti-Bacterial Agents; Cephalosporins; Daptomycin; Endocarditis; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Salvage Therapy; Staphylococcal Infections; Treatment Outcome | 2016 |
High-Level Resistance of Staphylococcus aureus to β-Lactam Antibiotics Mediated by Penicillin-Binding Protein 4 (PBP4).
Topics: Anti-Bacterial Agents; beta-Lactams; Cephalosporins; Methicillin Resistance; Penicillin-Binding Proteins; Staphylococcal Infections; Staphylococcus aureus | 2017 |
Activity of ceftobiprole against Staphylococcus spec. isolates derived from foreign body associated infections.
Topics: Anti-Bacterial Agents; Cephalosporins; Foreign Bodies; Humans; Microbial Sensitivity Tests; Prosthesis-Related Infections; Staphylococcal Infections; Staphylococcus | 2018 |
Comparative activity of ceftobiprole against coagulase-negative staphylococci from the BSAC Bacteraemia Surveillance Programme, 2013-2015.
Topics: Anti-Infective Agents; Bacteremia; Cephalosporins; Drug Resistance, Bacterial; Epidemiological Monitoring; Humans; Ireland; Microbial Sensitivity Tests; Staphylococcal Infections; Staphylococcus; United Kingdom | 2018 |
Disposition of ceftobiprole during continuous venous-venous hemodiafiltration (CVVHDF) in a single critically ill patient.
Topics: Anti-Bacterial Agents; Cephalosporins; Critical Illness; Fatal Outcome; Hemofiltration; Humans; Male; Middle Aged; Pneumonia | 2018 |
Bactericidal activity of ceftobiprole combined with different antibiotics against selected Gram-positive isolates.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Bacterial; Drug Synergism; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Microbial Viability; Time Factors | 2019 |
Ceftobiprole activity when tested against contemporary bacteria causing bloodstream infections in the United States (2016-2017).
Topics: Anti-Bacterial Agents; Bacteremia; Cephalosporins; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests; United States | 2019 |
Validation and Application of an HPLC-DAD Method for Routine Therapeutic Drug Monitoring of Ceftobiprole.
Topics: Aged; Anti-Bacterial Agents; Calibration; Cephalosporins; Chromatography, High Pressure Liquid; Drug Monitoring; Female; Humans; Male; Seizures | 2019 |
Molecular docking and spectroscopic studies on the interaction of new fifth-generation antibacterial drug ceftobiprole with calf thymus DNA.
Topics: Anti-Bacterial Agents; Cell Survival; Cephalosporins; DNA; Humans; Hydrogen Bonding; MCF-7 Cells; Molecular Docking Simulation; Nucleic Acid Conformation; Thermodynamics | 2019 |
Genotypic analysis of Italian MRSA strains exhibiting low-level ceftaroline and ceftobiprole resistance.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Ceftaroline; Cephalosporins; Daptomycin; Drug Resistance, Multiple, Bacterial; Drug Synergism; Genotype; Humans; Italy; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Mutation; Penicillin-Binding Proteins; Staphylococcal Infections | 2019 |
Ceftobiprole for the treatment of infective endocarditis: A case series.
Topics: Adult; Aged; Aged, 80 and over; Cephalosporins; Daptomycin; Drug Therapy, Combination; Endocarditis; Female; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Male; Middle Aged; Treatment Outcome | 2020 |
Introduction.
Topics: Anti-Bacterial Agents; Bacteremia; Ceftaroline; Cephalosporins; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Pneumonia, Bacterial; Pseudomonas; Staphylococcal Infections; Staphylococcus aureus | 2019 |
In vitro evidence of the synergistic interaction of ceftopibrole and other antibiotics against multidrug-resistant Gram-negative isolates.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Drug Resistance, Multiple, Bacterial; Drug Synergism; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Microbial Viability | 2019 |
Staphylococcus aureus from hospital-acquired pneumonia from an Italian nationwide survey: activity of ceftobiprole and other anti-staphylococcal agents, and molecular epidemiology of methicillin-resistant isolates.
Topics: Anti-Bacterial Agents; Bacterial Typing Techniques; Cephalosporins; Cross Infection; DNA, Bacterial; Humans; Italy; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Molecular Epidemiology; Multilocus Sequence Typing; Pneumonia, Bacterial; Prevalence; Public Health Surveillance; Staphylococcal Infections; Staphylococcus aureus; Virulence; Whole Genome Sequencing | 2019 |
In vitro susceptibility testing of ceftobiprole against 880 European respiratory tract infection isolates of methicillin-resistant Staphylococcus aureus followed by whole genome sequencing of ceftobiprole-resistant isolates.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Cephalosporins; Drug Resistance, Bacterial; Europe; Genome, Bacterial; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Mutation; Penicillin-Binding Proteins; Respiratory Tract Infections; Staphylococcal Infections; Whole Genome Sequencing | 2020 |
Antimicrobial susceptibility of plastic-associated bacteria isolated from the ocean to novel antibiotics (delafloxacin, meropenem/vaborbactam, ceftolozane/tazobactam, ceftobiprole) - Can environmental bacteria be predictors of persistence of antibiotic ac
Topics: Antarctic Regions; Anti-Bacterial Agents; Bacteria; Boronic Acids; Cephalosporins; Drug Resistance, Microbial; Fluoroquinolones; Islands; Meropenem; Oceans and Seas; Plastics; Polystyrenes; Tazobactam | 2020 |
Structural Insights into Ceftobiprole Inhibition of Pseudomonas aeruginosa Penicillin-Binding Protein 3.
Topics: Anti-Bacterial Agents; Binding Sites; Catalytic Domain; Cephalosporins; Crystallography, X-Ray; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Molecular Conformation; Penicillin-Binding Proteins; Protein Binding; Pseudomonas aeruginosa | 2020 |
Ceftobiprole: a potential empirical post-operative monotherapy in prosthetic joint infections.
Topics: Anti-Bacterial Agents; Cephalosporins; Coinfection; Enterobacteriaceae Infections; Female; Humans; Male; Microbial Sensitivity Tests; Prosthesis-Related Infections; Retrospective Studies; Staphylococcal Infections | 2020 |
Real-life experience with ceftobiprole in a tertiary-care hospital.
Topics: Cephalosporins; Humans; Methicillin-Resistant Staphylococcus aureus; Retrospective Studies; Tertiary Care Centers | 2020 |
Activity of ceftaroline versus ceftobiprole against staphylococci and pneumococci in the UK and Ireland: analysis of BSAC surveillance data.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Ireland; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Staphylococcus; Staphylococcus aureus; Streptococcus pneumoniae; United Kingdom | 2020 |
In vitro activity of ceftaroline and ceftobiprole against clinical isolates of Gram-positive bacteria from infective endocarditis: are these drugs potential options for the initial management of this disease?
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Endocarditis, Bacterial; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests | 2020 |
Ceftobiprole and pneumonia in adults admitted to the emergency department is it time to assess a new therapeutic algorithm?
Topics: Aged; Anti-Bacterial Agents; Cephalosporins; Community-Acquired Infections; Comorbidity; Emergency Service, Hospital; Female; Humans; Male; Middle Aged; Pneumonia, Bacterial; Retrospective Studies; Severity of Illness Index | 2021 |
Real-life experience with ceftobiprole in Canada: Results from the CLEAR (CanadianLEadership onAntimicrobialReal-life usage) registry.
Topics: Anti-Bacterial Agents; Canada; Cephalosporins; Humans; Methicillin-Resistant Staphylococcus aureus; Registries | 2021 |
Clinical outcomes of ceftobiprole in the treatment of acute bacterial skin and skin structure infections.
Topics: Cephalosporins; Gram-Positive Bacteria | 2021 |
Efficacy and safety of ceftobiprole in patients aged 65 years or older: a
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Cephalosporins; Clinical Trials, Phase III as Topic; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Pneumonia; Skin Diseases, Bacterial; Treatment Outcome | 2021 |
Real-life experience in the use of ceftobiprole for the treatment of nosocomial pneumonia: a case series.
Topics: Cephalosporins; Cross Infection; Healthcare-Associated Pneumonia; Humans | 2021 |
Simple and accurate quantitative analysis of cefiderocol and ceftobiprole in human plasma using liquid chromatography-isotope dilution tandem mass spectrometry: interest for their therapeutic drug monitoring and pharmacokinetic studies.
Topics: Cefiderocol; Cephalosporins; Chromatography, High Pressure Liquid; Chromatography, Liquid; Drug Monitoring; Humans; Isotopes; Reproducibility of Results; Tandem Mass Spectrometry | 2021 |
Surveillance of ceftobiprole against Gram-positive and Gram-negative clinical isolates from 2018 from different European territories.
Topics: Anti-Bacterial Agents; Cephalosporins; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests | 2021 |
Model-Based Approach for Optimizing Ceftobiprole Dosage in Pediatric Patients.
Topics: Adult; Aged; Anti-Bacterial Agents; Cephalosporins; Child; Community-Acquired Infections; Humans; Infant, Newborn; Infusions, Intravenous | 2021 |
The antimicrobial activity of ceftobiprole against Methicillin-resistant
Topics: Anti-Bacterial Agents; Cephalosporins; Hospitals; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Pharmaceutical Preparations; Pseudomonas aeruginosa; Retrospective Studies; Saudi Arabia; Staphylococcal Infections; Tertiary Healthcare | 2022 |
Ceftobiprole and daptomycin concentrations in valve tissue in a patient with mitralic native valve endocarditis.
Topics: Anti-Bacterial Agents; Cephalosporins; Daptomycin; Endocarditis; Endocarditis, Bacterial; Humans; Microbial Sensitivity Tests; Staphylococcal Infections | 2022 |
Susceptibility of ceftobiprole against Gram-positive and Gram-negative clinical isolates from 2019 from different European territories.
Topics: Anti-Bacterial Agents; Cephalosporins; Microbial Sensitivity Tests; Staphylococcus aureus | 2022 |
Ceftobiprole activity against Gram-positive and Gram-negative pathogens causing bone and joint infections in the United States from 2016 to 2020.
Topics: Anti-Bacterial Agents; Arthritis, Infectious; Cephalosporins; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Staphylococcus aureus; United States | 2022 |
Emergence of methicillin-resistant Staphylococcus epidermidis resistant to linezolid: activity of ceftaroline versus ceftobiprole in a French University Hospital.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Hospitals; Humans; Linezolid; Methicillin Resistance; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Staphylococcal Infections; Staphylococcus epidermidis | 2022 |
Study of Degradation Kinetics and Structural Analysis of Related Substances of Ceftobiprole by HPLC with UV and MS/MS Detection.
Topics: Cephalosporins; Drug Stability; Kinetics; Methicillin-Resistant Staphylococcus aureus; Tandem Mass Spectrometry | 2022 |
Pharmacokinetics/pharmacodynamics of ceftobiprole in patients on extracorporeal membrane oxygenation.
Topics: Cephalosporins; Cohort Studies; Critical Illness; Extracorporeal Membrane Oxygenation; Humans; Retrospective Studies | 2023 |
CEFTO-CURE study: CEFTObiprole Clinical Use in Real-lifE - a multi-centre experience in Italy.
Topics: Adult; Aged; Anti-Bacterial Agents; Cephalosporins; Cross Infection; Humans; Italy; Male; Middle Aged; Pneumonia; Retrospective Studies; Sepsis | 2023 |
Clinical results with the use of ceftaroline and ceftobiprole: real-life experience in a tertiary care hospital.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Retrospective Studies; Tertiary Care Centers | 2023 |
Efficacy of ceftobiprole in a murine model of bacteremia and disseminated infection.
Topics: Animals; Anti-Bacterial Agents; Bacteremia; Cephalosporins; Disease Models, Animal; Humans; Methicillin-Resistant Staphylococcus aureus; Mice; Microbial Sensitivity Tests; Staphylococcal Infections; Staphylococcus aureus | 2023 |